'On standalone basis
Quarter ended December 2025 compared with Quarter ended December 2024.
Net sales (including other operating income) of Pfizer has increased 19.90% to Rs 645.03 crore. Operating profit margin has jumped from 27.14% to 35.38%, leading to 56.31% rise in operating profit to Rs 228.19 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 13.10% to 10.70%. Purchase of finished goods cost rose from 20.44% to 22.92%. Employee cost decreased from 18.74% to 15.84%. Other expenses fell from 19.30% to 14.49%.
Other income fell 10.64% to Rs 38.21 crore. PBIDT rose 41.14% to Rs 266.4 crore. Provision for interest up 31.79% to Rs 1.99 crore.
PBDT rose 41.21% to Rs 264.41 crore. Provision for depreciation down 3.65% to Rs 14.26 crore.
Profit before tax grew 45.06% to Rs 250.15...
Pleaselogin & subscribe to view the full report.
More Reports
-
(26-Feb-2026)
Foseco India
Net down 35% on higher EO Exp
-
(26-Feb-2026)
KSB
Net up 11%, sales up 8%
-
(26-Feb-2026)
Sanofi India
OP down 23.67%
-
(25-Feb-2026)
Schaeffler India
Revenue jumps 28% and profit spurts 36% in Q4CY25
|
|